Zoetis Inc. (ZTS) Earns “Buy” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their buy rating on shares of Zoetis Inc. (NYSE:ZTS) in a report published on Wednesday. Cantor Fitzgerald currently has a $75.00 price target on the stock.

ZTS has been the subject of several other research reports. Deutsche Bank AG reissued a buy rating and issued a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Zacks Investment Research raised shares of Zoetis from a hold rating to a buy rating and set a $67.00 price objective for the company in a research report on Wednesday, May 10th. Argus reissued a buy rating and issued a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. Stifel Nicolaus reissued a buy rating and issued a $65.00 price objective on shares of Zoetis in a research report on Friday, September 1st. Finally, Hilliard Lyons initiated coverage on shares of Zoetis in a research report on Tuesday, June 20th. They issued a buy rating and a $77.00 price objective for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the stock. Zoetis presently has a consensus rating of Buy and a consensus price target of $65.44.

Zoetis (ZTS) opened at 64.70 on Wednesday. The firm has a 50-day moving average of $61.87 and a 200 day moving average of $58.97. Zoetis has a 12 month low of $46.86 and a 12 month high of $65.12. The stock has a market cap of $31.65 billion, a PE ratio of 36.57 and a beta of 1.02.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the prior year, the business earned $0.49 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Analysts anticipate that Zoetis will post $2.34 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/09/10/zoetis-inc-zts-earns-buy-rating-from-cantor-fitzgerald.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Zoetis by 3.9% during the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after acquiring an additional 1,412,829 shares during the last quarter. Vanguard Group Inc. boosted its stake in Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after acquiring an additional 910,265 shares during the last quarter. State Street Corp boosted its stake in Zoetis by 4.9% during the 1st quarter. State Street Corp now owns 21,256,557 shares of the company’s stock valued at $1,134,453,000 after acquiring an additional 986,680 shares during the last quarter. Morgan Stanley boosted its stake in Zoetis by 182.5% during the 1st quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after acquiring an additional 9,442,207 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after acquiring an additional 3,695,449 shares during the last quarter. Hedge funds and other institutional investors own 93.31% of the company’s stock.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply